Mitigating Multiple Sclerosis: Taking a Deep Dive into Emerging BTK Inhibitors
Released On
April 8, 2024
Expires On
April 8, 2025
Media Type
Internet
Completion Time
45 minutes
Specialty
Neurology, Pain Management, Primary Care
Topic(s)
Multiple Sclerosis
This activity is provided by Integrity CE, LLC.
This activity is supported by an educational grant from Sanofi.
Credit Available
- Physicians — maximum of .75 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity has been designed to meet the needs of neurologists, primary care physicians, nurse practitioners, physician assistants, and other clinicians who manage patients with multiple sclerosis (MS).
Program Overview
Every 5 minutes, someone is diagnosed with MS, according to the Multiple Sclerosis International Federation’s Atlas of MS. Along with 85% of other newly diagnosed patients with MS, they will be diagnosed with relapsing-remitting MS (RRMS), one of the four MS subtypes.
In 2024, five emerging Bruton’s tyrosine kinase (BTK) inhibitors are undergoing late-phase clinical investigation for MS, but most clinicians are likely unaware of their place in the development pipeline and the clinical data regarding their use in MS. This Deep Dive activity into recently published or released data about BTK inhibitors in MS will convey critical information to neurologists and other clinicians about this innovative approach to MS management.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify the role of BTK as a therapeutic target in the immunopathogenesis of MS
- Explain the mechanism of action of BTK inhibitors when used for MS
- Outline ideas for incorporating BTK inhibitors (when FDA approved) into therapeutic options for MS based on new and emerging efficacy and safety findings from clinical trials
Faculty
Daniel S. Reich, MD, PhD
Senior Investigator and Chief
Translational Neuroradiology Section
National Institute of Neurological Disorders and Stroke (NINDS)
National Institutes of Health (NIH), USA
He appears here in his private capacity, as an approved Outside Activity, and the views and opinions here do not represent those of NINDS or NIH.
Physician Accreditation Statement
Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Relevant Financial Relationship(s)
Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:
- Daniel S. Reich, MD, PhD
- NIH Cooperative Research and Development Agreements: Abata Therapeutics, Sanofi
The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 8, 2024 through April 8, 2025, participants must:
- Read the learning objectives
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed posttest with a score of 50% or better and a completed activity evaluation form.
Course Viewing Requirements
Supported Browsers:
Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
- Adobe® Flash® Player 10 plug-in should be downloaded
- Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information
For information about ACCME accreditation of this activity, please contact Integrity CE LLC, at (855) 835-4004 or [email protected].